CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03277729
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:42.320321+00:00
Published At: 2025-04-16T00:00:00+00:00
Record Updated At: 2026-01-05
Results Posted At: 2025-04-16
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma", "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Marginal Zone Lymphoma", "Refractory Transformed B-Cell Non-Hodgkin Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma", "Recurrent Central Nervous System Lymphoma", "Refractory Central Nervous System Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-05"
protocolSection.identificationModule.nctId: "NCT03277729"
protocolSection.identificationModule.officialTitle: "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-04-16"

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.